Skip to content
Yog Pharma
Central nervous systemAtypical antipsychotic (dopamine D2 partial agonist)

Aripiprazole is an atypical antipsychotic (dopamine D2 partial agonist) indicated for schizophrenia, bipolar I disorder, adjunctive treatment of major depressive disorder and irritability associated with autistic disorder. We supply it to US manufacturers of tablets, orally disintegrating tablets and oral solution.

CAS129722-12-9448.4 g/molC23H27Cl2N3O2
2D structure of Aripiprazole.

Data from PubChem (CID 60795) and FDA’s substance registry

CAS number

129722-12-9

Molecular formula

C23H27Cl2N3O2

Molecular weight

448.4g/mol

FDA UNII

IUPAC name

7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one

InChIKey

CEUORZQYGODEFX-UHFFFAOYSA-N

Appearance
White to off-white crystalline powder.
Solubility
Practically insoluble in water.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Has several anhydrous and hydrate crystal forms. State the polymorph and the particle size you developed with.

On the US market

Reference product
AbilifyNDA 021436
Approved ANDAs
27 with a marketed product
Approved forms and strengths
  • Tablet 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
  • Orally disintegrating tablet 10 mg, 15 mg, 20 mg, 30 mg
  • Oral solution 1 mg/mL
  • Extended-release injectable suspension 300 mg, 300 mg per vial, 400 mg, 400 mg per vial, 720 mg/2.4 mL, 960 mg/3.2 mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com